Biopartnering Seminar Series - Patented Drugs in Canada: The Impact of International Trade Deals & Global Harmonization

Tuesday, January 24, 2017 - 6:30pm

Patented Drugs in Canada: The Impact of International Trade Deals & Global Harmonization - Geoff Mowatt, Partner, DLA Piper Canada LLP

The global harmonization of Canada’s approach to patents and data protection for pharmaceuticals and biologics has been a key issue in negotiating international trade agreements in recent years, such as TPP and CETA. From the promise doctrine for patent utility to data protection for biologics to revamping the regulations that frame pharmaceutical litigation in Canada, the impact of global harmonization has been significant and will continue to shape how Canada’s patent and regulatory regime intersect with the pharma/biopharma industry for years to come.    

Geoff Mowatt is a partner of DLA Piper Canada LLP and is certified by the Law Society of Upper Canada as a specialist in Intellectual Property (Patent) Law. His practice focuses primarily on patent litigation and pharmaceutical/biopharmaceutical litigation under the Patented Medicines (Notice of Compliance) Regulations. Geoff is the Chair of the Biotechnology Committee of the Canadian Bar Association. Geoff’s experience ranges from preparing pre-litigation opinions and drafting notices of allegation, to appearing before the Ontario Court, Federal Court, and Federal Court of Appeal. He has worked with counsel in other jurisdictions, including the United States, Europe and Australia, to co-ordinate the Canadian aspect of multi-jurisdictional patent disputes. Geoff presents frequently and has authored or co-authored various articles on patent and regulatory issues relating to pharmaceutical, biologics/biosimilars, biotechnology and medical devices in Canada.  Geoff received his LL.B. from Osgoode Hall Law School and holds a M.Sc. from the University of Toronto.